Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy
Mittendorf EA, Kantor O, Weiss A, Richardson E, Garrido-Castro A, Portnow LH, Krop IE, Lin NU, Winer EP, Tolaney SM, King TA. Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. Annals Of Surgical Oncology 2022, 30: 100-106. PMID: 35941343, DOI: 10.1245/s10434-022-12357-8.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNational Cancer DatabaseNormal clinical examinationAxillary ultrasoundNegative clinical examinationClinical examinationUpfront surgeryCT2 tumorsInstitutional databaseBreast cancerEarly-stage triple-negative breast cancerStage triple-negative breast cancerAddition of immunotherapyNodal positivity ratePathologic nodal statusNode-positive patientsEvent-free survivalNode-positive diseaseRisk-benefit ratioCT1-2N0NCDB cohortPreoperative immunotherapyResultsFor patientsPositive nodesPreoperative chemotherapy